Author:
Meddahi Sadia,Samama Meyer Michel
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Hematology,General Medicine
Reference20 articles.
1. The pathogenesis of coronary artery disease and the acute coronary syndromes;Fuster;N Engl J Med,1992
2. Coagulation inflammation and myocardial dysfunction in unstable coronary artery disease and the influence of glycoprotein IIb/IIIa inhibition and low molecular weight heparin;James;Med Sci,2004
3. Haemostatic and inflammation markers in acute coronary syndromes and its relation ship with adverse cardiovascular events;Diaz;Arch Cardio Res,2006
4. I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet in various categories of patients. Antiplatelet trialists. Collaboration.;BMJ,1994
5. Unfractionated heparin and low molecular heparin in acute coronary syndromes without ST elevation: a meta-analysis;Eikelboom;Lancet,2000
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. In vitro comparison of the novel, dual-acting FIIa/FXa-inhibitor EP217609C101, unfractionated heparin, enoxaparin, and fondaparinux in preventing cardiac catheter thrombosis;Journal of Thrombosis and Thrombolysis;2013-07-03
2. Bivalirudin in Combination with Heparin to Control Mesenchymal Cell Procoagulant Activity;PLoS ONE;2012-08-10
3. Effect of food on the pharmacokinetics and pharmacodynamics of R1663, an oral factor Xa inhibitor, in healthy male volunteers;Int. Journal of Clinical Pharmacology and Therapeutics;2012-08-01
4. Crossover Dose Escalation Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of Single Doses of R1663, an Oral Factor Xa Inhibitor, in Healthy Male Volunteers;The Journal of Clinical Pharmacology;2012-04
5. Safety, pharmacokinetics and pharmacodynamics of multiple ascending doses of R1663, an oral factor Xa inhibitor, in healthy young subjects coupled with exploration of influence of gender and age;Thrombosis and Haemostasis;2012